food and drug administration, Olema Oncology
Olema Pharmaceuticals Shares Rise 8.9% on FDA Approval of Cancer Drug Application
Olema Pharmaceuticals shares rose 5.3% in premarket trading Monday after its investigational new drug application for OP-3136 was approved by the Food and Drug Administration. Shares were trading around $11. The stock is down 26% on the year.
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a ...
"We are very pleased to have received notification from the FDA that OP-3136 may proceed into the clinic,” said David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema Oncology.
Olema presented Phase 1b/2 trial data for palazestrant combined with Novartis's Kisqali in ER-positive, HER2-negative breast ...
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...
GlobalData on MSN9d
Novartis and Olema expand alliance with $250m to boost breast cancer trialsOlema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
Olema has also entered into a securities purchase agreement for the private placement of approximately $250.0 million of common stock and pre-funded warrants to purchase common stock with new and ...
(RTTNews) - Olema Oncology (OLMA), a clinical-stage biopharmaceutical company, on Monday announced a new clinical trial collaboration and supply agreement with Novartis (NVS) to advance its ...
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
Olema Oncology SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused ...
Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and ...
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback